Chapter 3: Management of progression and complications of CKD

Kidney International Supplements

Volumn 3, Issue 1, 2013, Pages 73-90

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85096669226     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2012.66     Document Type: Article

References (160)

1. KDIGO CKD-MBD Work Group., KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl, 2009, S1–130.
2. Seliger, S.L., Zhan, M., Hsu, V.D., et al. Chronic kidney disease adversely influences patient safety. J Am Soc Nephrol 19 (2008), 2414–2419.
3. Guy, M., Newall, R., Borzomato, J., et al. Diagnostic accuracy of the urinary albumin: creatinine ratio determined by the CLINITEK Microalbumin and DCA 2000+ for the rule-out of albuminuria in chronic kidney disease. Clin Chim Acta 399 (2009), 54–58.
4. Mittalhenkle, A., Stehman-Breen, C.O., Shlipak, M.G., et al. Cardiovascular risk factors and incident acute renal failure in older adults: the cardiovascular health study. Clin J Am Soc Nephrol 3 (2008), 450–456.
5. Uchino, S., Kellum, J.A., Bellomo, R., et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294 (2005), 813–818.
6. Hoste, E.A., Lameire, N.H., Vanholder, R.C., et al. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol 14 (2003), 1022–1030.
7. McCullough, P.A., Wolyn, R., Rocher, L.L., et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103 (1997), 368–375.
8. Mehran, R., Aymong, E.D., Nikolsky, E., et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44 (2004), 1393–1399.
9. Mehta, R.H., Grab, J.D., O'Brien, S.M., et al. Bedside tool for predicting the risk of postoperative dialysis in patients undergoing cardiac surgery. Circulation 114 (2006), 2208–2216.
10. Thakar, C.V., Worley, S., Arrigain, S., et al. Influence of renal dysfunction on mortality after cardiac surgery: modifying effect of preoperative renal function. Kidney Int 67 (2005), 1112–1119.
11. Waikar, S.S., Liu, K.D., Chertow, G.M., Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol 3 (2008), 844–861.
12. Yegenaga, I., Hoste, E., Van Biesen, W., et al. Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study. Am J Kidney Dis 43 (2004), 817–824.
13. Parfrey, P.S., Griffiths, S.M., Barrett, B.J., et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 320 (1989), 143–149.
14. Browner, W.S., Li, J., Mangano, D.T., In-hospital and long-term mortality in male veterans following noncardiac surgery. The Study of Perioperative Ischemia Research Group. JAMA 268 (1992), 228–232.
15. Hou, S.H., Bushinsky, D.A., Wish, J.B., et al. Hospital-acquired renal insufficiency: a prospective study. Am J Med 74 (1983), 243–248.
16. Singh, P., Rifkin, D.E., Blantz, R.C., Chronic kidney disease: an inherent risk factor for acute kidney injury?. Clin J Am Soc Nephrol 5 (2010), 1690–1695.
17. Lafrance, J.P., Djurdjev, O., Levin, A., Incidence and outcomes of acute kidney injury in a referred chronic kidney disease cohort. Nephrol Dial Transplant 25 (2010), 2203–2209.
18. Chapin, E., Zhan, M., Hsu, V.D., et al. Adverse safety events in chronic kidney disease: the frequency of “multiple hits”. Clin J Am Soc Nephrol 5 (2010), 95–101.
19. Chertow, G.M., Christiansen, C.L., Cleary, P.D., et al. Prognostic stratification in critically ill patients with acute renal failure requiring dialysis. Arch Intern Med 155 (1995), 1505–1511.
20. Chertow, G.M., Soroko, S.H., Paganini, E.P., et al. Mortality after acute renal failure: models for prognostic stratification and risk adjustment. Kidney Int 70 (2006), 1120–1126.
21. Mehta, R.L., Pascual, M.T., Gruta, C.G., et al. Refining predictive models in critically ill patients with acute renal failure. J Am Soc Nephrol 13 (2002), 1350–1357.
22. Paganini, E.P., Larive, B., Kanagasundaram, N.S., Severity scores and outcomes with acute renal failure in the ICU setting. Contrib Nephrol, 2001, 181–195.
23. Uchino, S., Bellomo, R., Morimatsu, H., et al. External validation of severity scoring systems for acute renal failure using a multinational database. Crit Care Med 33 (2005), 1961–1967.
24. Waikar, S.S., Curhan, G.C., Wald, R., et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 17 (2006), 1143–1150.
25. Khosla, N., Soroko, S.B., Chertow, G.M., et al. Preexisting chronic kidney disease: a potential for improved outcomes from acute kidney injury. Clin J Am Soc Nephrol 4 (2009), 1914–1919.
26. Fouque, D., Laville, M., Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev, 2009, CD001892.
27. Fouque, D., Laville, M., Boissel, J.P., et al. Controlled low protein diets in chronic renal insufficiency: meta-analysis. BMJ 304 (1992), 216–220.
28. Kasiske, B.L., Lakatua, J.D., Ma, J.Z., et al. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 31 (1998), 954–961.
29. Pedrini, M.T., Levey, A.S., Lau, J., et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 124 (1996), 627–632.
30. Robertson, L., Waugh, N., Robertson, A., Protein restriction for diabetic renal disease. Cochrane Database Syst Rev, 2009, CD002181.
31. Menon, V., Kopple, J.D., Wang, X., et al. Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 53 (2009), 208–217.
32. Knight, E.L., Stampfer, M.J., Hankinson, S.E., et al. The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency. Ann Intern Med 138 (2003), 460–467.
33. Chaturvedi, S., Jones, C., Protein restriction for children with chronic renal failure. Cochrane Database Syst Rev, 2007, CD006863.
34. National Kidney Foundation., KDOQI clinical practice guideline for diabetes and chronic kidney disease: 2012 Update. Am J Kidney Dis 60 (2012), 850–886.
35. Patel, A., MacMahon, S., Chalmers, J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
36. Ismail-Beigi, F., Craven, T., Banerji, M.A., et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376 (2010), 419–430.
37. Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
38. Nathan, D.M., Zinman, B., Cleary, P.A., et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 169 (2009), 1307–1316.
39. UK Prospective Diabetes Study (UKPDS) Group., Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
40. Ichikawa, H., Nagake, Y., Takahashi, M., et al. What is the best index of glycemic control in patients with diabetes mellitus on hemodialysis?. Nihon Jinzo Gakkai Shi 38 (1996), 305–308.
41. Joy, M.S., Cefalu, W.T., Hogan, S.L., et al. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 39 (2002), 297–307.
42. Nakao, T., Matsumoto, H., Okada, T., et al. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 37 (1998), 826–830.
43. Ng, J.M., Cooke, M., Bhandari, S., et al. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. Diabetes Care 33 (2010), 2310–2313.
44. Shima, K., Chujo, K., Yamada, M., et al. Lower value of glycated haemoglobin relative to glycaemic control in diabetic patients with end-stage renal disease not on haemodialysis. Ann Clin Biochem 49 (2012), 68–74.
45. Vos, F.E., Schollum, J.B., Coulter, C.V., et al. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring. Nephrology (Carlton) 17 (2012), 182–188.
46. American Diabetes Association., Executive summary: Standards of medical care in diabetes–2012. Diabetes Care 35:Suppl 1 (2012), S4–S10.
47. Jones-Burton, C., Mishra, S.I., Fink, J.C., et al. An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol 26 (2006), 268–275.
48. Swift, P.A., Markandu, N.D., Sagnella, G.A., et al. Modest salt reduction reduces blood pressure and urine protein excretion in black hypertensives: a randomized control trial. Hypertension 46 (2005), 308–312.
49. Hoffmann, I.S., Cubeddu, L.X., Increased blood pressure reactivity to dietary salt in patients with the metabolic syndrome. J Hum Hypertens 21 (2007), 438–444.
50. Bellizzi, V., Di Iorio, B.R., De Nicola, L., et al. Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney Int 71 (2007), 245–251.
51. Slagman, M.C., Waanders, F., Hemmelder, M.H., et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ, 343, 2011, d4366.
52. Bellomo, G., Venanzi, S., Verdura, C., et al. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 56 (2010), 264–272.
53. Iseki, K., Ikemiya, Y., Inoue, T., et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 44 (2004), 642–650.
54. Mok, Y., Lee, S.J., Kim, M.S., et al. Serum uric acid and chronic kidney disease: the Severance cohort study. Nephrol Dial Transplant 27 (2012), 1831–1835.
55. Wen, C.P., David Cheng, T.Y., Chan, H.T., et al. Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk. Am J Kidney Dis 56 (2010), 273–288.
56. Yamada, T., Fukatsu, M., Suzuki, S., et al. Elevated serum uric acid predicts chronic kidney disease. Am J Med Sci 342 (2011), 461–466.
57. Goicoechea, M., de Vinuesa, S.G., Verdalles, U., et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5 (2010), 1388–1393.
58. Siu, Y.P., Leung, K.T., Tong, M.K., et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47 (2006), 51–59.
59. Kanbay, M., Huddam, B., Azak, A., et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 6 (2011), 1887–1894.
60. Kanbay, M., Ozkara, A., Selcoki, Y., et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 39 (2007), 1227–1233.
61. Kao, M.P., Ang, D.S., Gandy, S.J., et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 22 (2011), 1382–1389.
62. Saito, J., Matsuzawa, Y., Ito, H., et al. The alkalizer citrate reduces serum uric Acid levels and improves renal function in hyperuricemic patients treated with the xanthine oxidase inhibitor allopurinol. Endocr Res 35 (2010), 145–154.
63. Malaguarnera, M., Vacante, M., Russo, C., et al. A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. Expert Opin Pharmacother 10 (2009), 737–742.
64. Miao, Y., Ottenbros, S.A., Laverman, G.D., et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 58 (2011), 2–7.
65. Johansen, K.L., Exercise and chronic kidney disease: current recommendations. Sports Med 35 (2005), 485–499.
66. Johansen, K.L., Chertow, G.M., Ng, A.V., et al. Physical activity levels in patients on hemodialysis and healthy sedentary controls. Kidney Int 57 (2000), 2564–2570.
67. Padilla, J., Krasnoff, J., Da Silva, M., et al. Physical functioning in patients with chronic kidney disease. J Nephrol 21 (2008), 550–559.
68. Beddhu, S., Baird, B.C., Zitterkoph, J., et al. Physical activity and mortality in chronic kidney disease (NHANES III). Clin J Am Soc Nephrol 4 (2009), 1901–1906.
69. Churchill, D.N., Torrance, G.W., Taylor, D.W., et al. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med 10 (1987), 14–20.
70. DeOreo, P.B., Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis 30 (1997), 204–212.
71. Booth, F.W., Gordon, S.E., Carlson, C.J., et al. Waging war on modern chronic diseases: primary prevention through exercise biology. J Appl Physiol 88 (2000), 774–787.
72. Dickinson, H.O., Mason, J.M., Nicolson, D.J., et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 24 (2006), 215–233.
73. Stewart, K.J., Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. JAMA 288 (2002), 1622–1631.
74. Daul, A.E., Schafers, R.F., Daul, K., et al. Exercise during hemodialysis. Clin Nephrol 61:Suppl 1 (2004), S26–S30.
75. Deligiannis, A., Cardiac adaptations following exercise training in hemodialysis patients. Clin Nephrol 61:Suppl 1 (2004), S39–S45.
76. Liu, S.H., C, LC, Yeh SH, et al. Effect of exercise training on hemodialysis. Journal of the Formosan Medical Association 6 (2002), 129–142.
77. Mustata, S., Chan, C., Lai, V., et al. Impact of an exercise program on arterial stiffness and insulin resistance in hemodialysis patients. J Am Soc Nephrol 15 (2004), 2713–2718.
78. Ouzouni, S., Kouidi, E., Sioulis, A., et al. Effects of intradialytic exercise training on health-related quality of life indices in haemodialysis patients. Clin Rehabil 23 (2009), 53–63.
79. Storer, T.W., Casaburi, R., Sawelson, S., et al. Endurance exercise training during haemodialysis improves strength, power, fatigability and physical performance in maintenance haemodialysis patients. Nephrol Dial Transplant 20 (2005), 1429–1437.
80. Vaitkevicius, P.V., Fleg, J.L., Engel, J.H., et al. Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation 88 (1993), 1456–1462.
81. Mustata, S., Groeneveld, S., Davidson, W., et al. Effects of exercise training on physical impairment, arterial stiffness and health-related quality of life in patients with chronic kidney disease: a pilot study. Int Urol Nephrol 43 (2011), 1133–1141.
82. Szromba, C., Thies, M.A., Ossman, S.S., Advancing chronic kidney disease care: new imperatives for recognition and intervention. Nephrol Nurs J 29 (2002), 547–559.
83. Chen, P.Y., Huang, Y.C., Kao, Y.H., et al. Effects of an exercise program on blood biochemical values and exercise stage of chronic kidney disease patients. J Nurs Res 18 (2010), 98–107.
84. Tobita, I., Suzuki, S., Kobayashi, T., et al. A programme to encourage participation of haemodialysis patients in an exercise regimen. J Ren Care 35 (2009), 48–53.
85. van Vilsteren, M.C., de Greef, M.H., Huisman, R.M., The effects of a low-to-moderate intensity pre-conditioning exercise programme linked with exercise counselling for sedentary haemodialysis patients in The Netherlands: results of a randomized clinical trial. Nephrol Dial Transplant 20 (2005), 141–146.
86. Kosmadakis, G.C., John, S.G., Clapp, E.L., et al. Benefits of regular walking exercise in advanced pre-dialysis chronic kidney disease. Nephrol Dial Transplant 27 (2012), 997–1004.
87. Hall, J.E., Crook, E.D., Jones, D.W., et al. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 324 (2002), 127–137.
88. Wahba, I.M., Mak, R.H., Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2 (2007), 550–562.
89. Wang, Y., Chen, X., Song, Y., et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 73 (2008), 19–33.
90. Hobbs, H., Farmer, C., Irving, J., et al. Is high body mass index independently associated with diminished glomerular filtration rate? An epidemiological study. J Ren Care 37 (2011), 148–154.
91. Mohsen, A., Brown, R., Hoefield, R., et al. Body mass index has no effect on rate of progression of chronic kidney disease in subjects with type 2 diabetes mellitus. J Nephrol, 0, 2011.
92. Burton, J.O., Gray, L.J., Webb, D.R., et al. Association of anthropometric obesity measures with chronic kidney disease risk in a non-diabetic patient population. Nephrol Dial Transplant 27 (2012), 1860–1866.
93. Kasiske, B.L., Napier, J., Glomerular sclerosis in patients with massive obesity. Am J Nephrol 5 (1985), 45–50.
94. Hsu, C.Y., McCulloch, C.E., Iribarren, C., et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 144 (2006), 21–28.
95. Navaneethan, S.D., Yehnert, H., Moustarah, F., et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 4 (2009), 1565–1574.
96. Afshinnia, F., Wilt, T.J., Duval, S., et al. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant 25 (2010), 1173–1183.
97. Orth, S.R., Hallan, S.I., Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients–absence of evidence or evidence of absence?. Clin J Am Soc Nephrol 3 (2008), 226–236.
98. Jungers, P., Massy, Z.A., Nguyen Khoa, T., et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant 12 (1997), 2597–2602.
99. Muntner, P., He, J., Astor, B.C., et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 16 (2005), 529–538.
100. Myllymaki, J., Syrjanen, J., Helin, H., et al. Vascular diseases and their risk factors in IgA nephropathy. Nephrol Dial Transplant 21 (2006), 1876–1882.
101. Shlipak, M.G., Fried, L.F., Cushman, M., et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293 (2005), 1737–1745.
102. Chase, H.P., Garg, S.K., Marshall, G., et al. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 265 (1991), 614–617.
103. Gambaro, G., Bax, G., Fusaro, M., et al. Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus. Diabetes Nutr Metab 14 (2001), 337–342.
104. Hallan, S.I., Orth, S.R., Smoking is a risk factor in the progression to kidney failure. Kidney Int 80 (2011), 516–523.
105. Sawicki, P.T., Didjurgeit, U., Muhlhauser, I., et al. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 17 (1994), 126–131.
106. Sung, R.S., Althoen, M., Howell, T.A., et al. Excess risk of renal allograft loss associated with cigarette smoking. Transplantation 71 (2001), 1752–1757.
107. Inker, L.A., Coresh, J., Levey, A.S., et al. Estimated GFR, albuminuria, and complications of chronic kidney disease. J Am Soc Nephrol 22 (2011), 2322–2331.
108. Levin, A., Bakris, G.L., Molitch, M., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71 (2007), 31–38.
109. World Health Organization., Worldwide prevalence of anaemia 1993–2005: WHO global database on anaemia, In: de Benoist B, McLean E, Egli I, and Cogswell M (eds), 2008.
110. Beall, C.M., Goldstein, M.C., Hemoglobin concentration of pastoral nomads permanently resident at 4,850-5,450 meters in Tibet. Am J Phys Anthropol 73 (1987), 433–438.
111. Cresanta, J.L., Croft, J.B., Webber, L.S., et al. Racial difference in hemoglobin concentration of young adults. Prev Med 16 (1987), 659–669.
112. Meyers, L.D., Habicht, J.P., Johnson, C.L., Components of the difference in hemoglobin concentrations in blood between black and white women in the United States. Am J Epidemiol 109 (1979), 539–549.
113. Pan, W.H., Habicht, J.P., The non-iron-deficiency-related difference in hemoglobin concentration distribution between blacks and whites and between men and women. Am J Epidemiol 134 (1991), 1410–1416.
114. Centers for Disease Control and Prevention., CDC criteria for anemia in children and childbearing-aged women. MMWR Morb Mortal Wkly Rep 38 (1989), 400–404.
115. Levin, A., Djurdjev, O., Thompson, C., et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 46 (2005), 799–811.
116. Pfeffer, M.A., Burdmann, E.A., Chen, C.Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 (2009), 2019–2032.
117. Roger, S.D., McMahon, L.P., Clarkson, A., et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 15 (2004), 148–156.
118. Moranne, O., Froissart, M., Rossert, J., et al. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 20 (2009), 164–171.
119. Vassalotti, J.A., Uribarri, J., Chen, S.C., et al. Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 51 (2008), S56–S68.
120. Stevens, L.A., Djurdjev, O., Cardew, S., et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 15 (2004), 770–779.
121. Gutierrez, O.M., Isakova, T., Andress, D.L., et al. Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. Kidney Int 73 (2008), 956–962.
122. Gutierrez, O.M., Farwell, W.R., Kermah, D., et al. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int 22 (2011), 1745–1753.
123. National Kidney Foundation., KDOQI clinical practice guideline for nutrition in children with CKD: 2008 update. Am J Kidney Dis 53 (2009), S1–124.
124. Nickolas, T.L., Leonard, M.B., Shane, E., Chronic kidney disease and bone fracture: a growing concern. Kidney Int 74 (2008), 721–731.
125. Bacchetta, J., Boutroy, S., Vilayphiou, N., et al. Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney disease. J Bone Miner Res 25 (2010), 849–857.
126. Nickolas, T.L., Stein, E., Cohen, A., et al. Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol 21 (2010), 1371–1380.
127. Nickolas, T.L., Cremers, S., Zhang, A., et al. Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol 22 (2011), 1560–1572.
128. Palmer, S.C., Hayen, A., Macaskill, P., et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 305 (2011), 1119–1127.
129. Adeney, K.L., Siscovick, D.S., Ix, J.H., et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 20 (2009), 381–387.
130. Moe, S.M., Zidehsarai, M.P., Chambers, M.A., et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 6 (2011), 257–264.
131. Sigrist, M.K., Chiarelli, G., Lim, L., et al. Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review. J Ren Care 35:Suppl 1 (2009), 71–78.
132. Lynch, K.E., Lynch, R., Curhan, G.C., et al. Prescribed dietary phosphate restriction and survival among hemodialysis patients. Clin J Am Soc Nephrol 6 (2011), 620–629.
133. Navaneethan, S.D., Palmer, S.C., Vecchio, M., et al. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev, 2011, CD006023.
134. Mehrotra, R., Kermah, D., Budoff, M., et al. Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 3 (2008), 1144–1151.
135. Navaneethan, S.D., Schold, J.D., Arrigain, S., et al. Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD. Am J Kidney Dis 58 (2011), 536–543.
136. Kandula, P., Dobre, M., Schold, J.D., et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 6 (2011), 50–62.
137. Palmer, S.C., McGregor, D.O., Craig, J.C., et al. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev, 2009, CD008175.
138. Miller, P.D., The kidney and bisphosphonates. Bone 49 (2011), 77–81.
139. Torregrosa, J.V., Ramos, A.M., Use of bisphosphonates in chronic kidney disease]. Nefrologia 30 (2010), 288–296.
140. Bhan, I., Dubey, A., Wolf, M., Diagnosis and management of mineral metabolism in CKD. J Gen Intern Med 25 (2010), 710–716.
141. Courtney, A.E., Leonard, N., McCloskey, M.C., et al. Bisphosphonate prescribing in chronic kidney disease. J R Coll Physicians Edinb 39 (2009), 4–9.
142. Ayus, J.C., Krothapalli, R.K., Effect of bicarbonate administration on cardiac function. Am J Med 87 (1989), 5–6.
143. Bailey, J.L., Wang, X., England, B.K., et al. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 97 (1996), 1447–1453.
144. Domrongkitchaiporn, S., Pongskul, C., Sirikulchayanonta, V., et al. Bone histology and bone mineral density after correction of acidosis in distal renal tubular acidosis. Kidney Int 62 (2002), 2160–2166.
145. Kovesdy, C.P., Anderson, J.E., Kalantar-Zadeh, K., Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrol Dial Transplant 24 (2009), 1232–1237.
146. Mak, R.H., Effect of metabolic acidosis on insulin action and secretion in uremia. Kidney Int 54 (1998), 603–607.
147. Menon, V., Tighiouart, H., Vaughn, N.S., et al. Serum bicarbonate and long-term outcomes in CKD. Am J Kidney Dis 56 (2010), 907–914.
148. Mitch, W.E., Price, S.R., Mechanisms activated by kidney disease and the loss of muscle mass. Am J Kidney Dis 38 (2001), 1337–1342.
149. Navaneethan, S.D., Schold, J.D., Arrigain, S., et al. Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease. Clin J Am Soc Nephrol 6 (2011), 2395–2402.
150. Raphael, K.L., Wei, G., Baird, B.C., et al. Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. Kidney Int 79 (2011), 356–362.
151. Shah, S.N., Abramowitz, M., Hostetter, T.H., et al. Serum bicarbonate levels and the progression of kidney disease: a cohort study. Am J Kidney Dis 54 (2009), 270–277.
152. Bright R. Reports of Medical Cases, Selected with a View of Illustrating the Symptoms and Cure of Diseases by a Reference to Morbid Anatomy, Volume 1. London: Brown & Green. 1827.
153. Osman, A.A., The value of alkalis in the treatment of chronic nephritis. Lancet 2 (1930), 945–959.
154. Lyon, D.M., Dunlop, D.M., Stewart, C.P., The alkaline treatment of chronic nephritis. Lancet 2 (1931), 1009–1013.
155. Rustom, R., Grime, J.S., Costigan, M., et al. Oral sodium bicarbonate reduces proximal renal tubular peptide catabolism, ammoniogenesis, and tubular damage in renal patients. Ren Fail 20 (1998), 371–382.
156. Mathur, R.P., Dash, S.C., Gupta, N., et al. Effects of correction of metabolic acidosis on blood urea and bone metabolism in patients with mild to moderate chronic kidney disease: a prospective randomized single blind controlled trial. Ren Fail 28 (2006), 1–5.
157. de Brito-Ashurst, I., Varagunam, M., Raftery, M.J., et al. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 20 (2009), 2075–2084.
158. Phisitkul, S., Khanna, A., Simoni, J., et al. Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 77 (2010), 617–623.
159. Husted, F.C., Nolph, K.D., Maher, J.F., NaHCO3 and NaC1 tolerance in chronic renal failure. J Clin Invest 56 (1975), 414–419.
160. Husted, F.C., Nolph, K.D., NaHCO3 and NaCl tolerance in chronic renal failure II. Clin Nephrol 7 (1977), 21–25.